Dyslipidemia Market Size, Share, Growth and Report 2024-2031

Dyslipidemia Market Size, Share, Industry, Forecast and Outlook (2024-2031)

<h2>Global Dyslipidemia Market&nbsp;Size, Share &amp; Trends Analysis Report By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2024 &ndash; 2031</h2>

<h3>Market Overview</h3>

<blockquote>
The global dyslipidemia market reached US$ 146 million in 2023 and is expected to reach US$ 219 million by 2031, growing at a CAGR of 5.6% during the forecast period 2024-2031.
</blockquote>

Dyslipidemia is&nbsp;an elevation&nbsp;of plasma cholesterol, triglycerides (TGs), or both, or a low high-density lipoprotein cholesterol (HDL-C) level that contributes to the development of&nbsp;atherosclerosis.&nbsp;Dyslipidemia may be primary (genetic) or secondary. Diagnosis is by measuring plasma levels of total cholesterol, TGs, and individual lipoproteins. Treatment involves dietary changes, exercise, and lipid-lowering drugs.

The primary factors driving the market are the increasing prevalence of cardiovascular diseases and dyslipidemia, advanced therapies for the treatment, and the rising geriatric population.

<h3>Market Scope</h3>

<table cellspacing="0" style="border-collapse:collapse">
	<tbody>
		<tr>
			<td style="background-color:#4472c4; border-bottom:1px solid #4472c4; border-left:1px solid #4472c4; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:top; width:312px">
			Metrics
			</td>
			<td style="background-color:#4472c4; border-bottom:1px solid #4472c4; border-left:1px solid #8eaadb; border-right:1px solid #4472c4; border-top:1px solid #4472c4; vertical-align:top; width:312px">
			Details
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:middle; width:312px">
			CAGR
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:middle; width:312px">
			5.6%
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Market Size&nbsp;
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			2022-2031
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Market Estimation Forecast Period
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			2024-2031
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Revenue Units
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Value (US$ Mn)&nbsp;
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Segments Covered
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Drug Class and Distribution Channel
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Regions Covered
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			North America, Europe, Asia-Pacific, South America, and Middle East &amp; Africa
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Largest Region
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			North America
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Fastest Growing Region
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Asia-Pacific
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Report Insights Covered
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Launches, Growth Strategies, Revenue Analysis, Porter&#39;s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights.
			</td>
		</tr>
	</tbody>
</table>

&nbsp;

For more details on this report - <a href="https://www.datamintelligence.com/download-sample/dyslipidemia-market" target="_blank">Request for Sample</a>

<h3>&nbsp;</h3>

<h3>Market Dynamics: Drivers</h3>

Increasing Prevalence of Cardiovascular Diseases and Dyslipidemia

The demand for the global dyslipidemia market is driven by multiple factors. Dyslipidemia is one of the important contributors to cardiovascular disease and type 2 diabetes. Dyslipidemia, characterized by abnormal lipid levels in the blood, is a significant risk factor for cardiovascular diseases (CVDs) such as heart attacks and strokes. The rising burden of CVDs and the demand for dyslipidemia management and treatment are expected to drive this market growth.

In addition, the prevalence of dyslipidemia, which includes conditions like high cholesterol, high triglycerides, and low HDL cholesterol, is rising globally due to factors like obesity, sedentary lifestyles, and poor dietary habits that are driving this market growth.&nbsp;

According to the population medicine research publication in June 2023, the prevalence of dyslipidemia was&nbsp;80.4%, 21.7% high total cholesterol (TC), 35.5% high triglycerides (TG), 20.2% high low-density lipoprotein cholesterol (LDL-C) and 68.9% low high-density lipoprotein cholesterol (HDL-C).

As per NCBI publication in July 2022, among the newly developed drugs is&nbsp;inclisiran, a small interfering RNA targeting hepatic PCSK9 synthesis led to increased LDL receptor recycling and potent LDL cholesterol reduction by 51% when used together with other lipid-lowering agents.

Restraints

Factors such as the high cost of R&amp;D, stringent regulatory requirements, patent expiry of existing drugs, patient compliance issues, and lack of awareness, high cost of the newly launched drugs among individuals, are expected to hamper the market.

<h3>Segment Analysis</h3>

The global dyslipidemia market is segmented based on drug class, distribution channel, and region.

The statin drugs segment accounted for approximately 59.6% of the global dyslipidemia market share

The statin drugs segment is expected to hold the largest market share over the forecast period.&nbsp; Statins are currently the first line of drugs in the treatment of dyslipidemia in children and adolescents. It would reduce the risk of major vascular events by lowering low-density lipoprotein cholesterol (LDL-C).

Moreover, key players in the market more focus on the treatment of dyslipidemia, and product launches and approvals would drive this segment growth. For instance, in June 2024, Daewoong Bio launched a new product that combines hyperlipidemia drug rosuvastatin with the dietary supplement Omega-3. It offers improvements in lipids and instability and tolerability compared to rosuvastatin alone.

Also, in July 2023, Novartis announced that the US Food and Drug Administration (FDA) has approved a label update for Leqvio (inclisiran) to enable earlier use in patients with elevated LDL-C who have an increased risk of heart disease, as an adjunct to diet and statin therapy.&nbsp;

<h3>Geographical Analysis</h3>

North America accounted for approximately 43.2% of the global dyslipidemia&nbsp; market share&nbsp;

North America region is expected to hold the largest market share over the forecast period. owing to the increasing prevalence of hypercholesteremia, increasing healthcare expenditure and the presence of a well-established healthcare infrastructure drive this market growth in this region.

Moreover, the rising prevalence of dyslipidemia in this region propels this market growth. 
According to new data from the Strong Heart Study (SHS), in March 2024, the young American Indian population, more than 70% of young adults and more than 50% of adolescents had dyslipidemia, and some had subclinical or clinical&nbsp;cardiovascular disease&nbsp;(CVD).

Moreover, the major number of key player presence, government awareness programs, and drug launches would help this market growth. For instance, in April 2024, the Canadian Cardiovascular Society (CCS) launched a national lipid screening awareness campaign to encourage people at risk of ASCVD to get their cholesterol, triglycerides, and Lp(a) levels tested and seek support from their healthcare provider.&nbsp;

Also, in November 2023, at the American Heart Association (AHA) Scientific Sessions in Philadelphia, Arrowhead Pharmaceuticals launched plozarsiran and zodasiran hold the potential to treat dyslipidemia.

<h3>Market Segmentation</h3>

&nbsp;By Drug Class&nbsp;

<ul>
	<li>Statin Drugs
	<ul>
		<li>Atorvastatin&nbsp;</li>
		<li>Lovastatin</li>
		<li>Rosuvastatin</li>
		<li>Others</li>
	</ul>
	</li>
	<li>Bile Acid Sequestrants</li>
	<li>Cholesterol Absorption Inhibitors</li>
	<li>Fibrates</li>
	<li>Niacins</li>
	<li>Omega-3 Fatty Acid Derivatives</li>
</ul>

By Distribution Channel&nbsp;

<ul>
	<li>Hospital Pharmacies</li>
	<li>Retail Pharmacies</li>
	<li>Online Pharmacies</li>
</ul>

By Region

<ul>
	<li>North America</li>
</ul>

<ul>
	<li>U.S.</li>
	<li>Canada</li>
	<li>Mexico</li>
</ul>

<ul>
	<li>Europe</li>
</ul>

<ul>
	<li>Germany</li>
	<li>U.K.</li>
	<li>France</li>
	<li>Spain</li>
	<li>Italy</li>
	<li>Rest of Europe</li>
</ul>

<ul>
	<li>South America</li>
</ul>

<ul>
	<li>Brazil</li>
	<li>Argentina</li>
	<li>Rest of South America</li>
</ul>

<ul>
	<li>Asia-Pacific</li>
</ul>

<ul>
	<li>China</li>
	<li>India</li>
	<li>Japan</li>
	<li>South Korea</li>
	<li>Rest of Asia-Pacific</li>
</ul>

<ul>
	<li>Middle East and Africa</li>
</ul>

<h3>Competitive Landscape</h3>

The major global players in the dyslipidemia market include AstraZeneca, Merck &amp; Co., Inc., Pfizer Inc., Sanofi, Abbott, Mylan N.V., Novartis Pharmaceuticals Corporation, Teva Pharmaceutical Industries Ltd, Lupin and Esperion Therapeutics, Inc among others.

<h3>Key Developments</h3>

<ul>
	<li>In January 2024, New Amsterdam Pharma Company N.V. developed oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (LDL-C), for whom existing therapies are not sufficiently effective or well-tolerated.</li>
	<li>In November 2023, CKD Pharm launched a reduced dosage of the dyslipidemia drug Lipilow. It was released the renewed versions of Lipilow&nbsp;were 20mg, 40mg, and 80mg.</li>
	<li>In October 2023, Zydus announced that it has received permission from CDSCO, India to initiate the Phase I clinical study of its novel PCSK9 inhibitor. It aims to treat Dyslipidemia by inhibiting PCSK9 with a novel entity.</li>
	<li>In October 2022, Eli&nbsp;Lilly&nbsp;and Company announced that the&nbsp;U.S. Food and Drug Administration&nbsp;(FDA) has granted Fast Track designation for the investigation of tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities.</li>
	<li>In September 2022, Servier is launching a new edition of the &ldquo;#BecauseISaySo&rdquo; prevention campaign in over 40 countries. The &ldquo;TakeYourMedicine&rdquo; component focuses attention on the need to take blood pressure medication and, for the first time, cholesterol medication.</li>
	<li>In May 2022, Zydus Lifesciences launched in India its&nbsp;Bempedoic acid&nbsp;drug under the&nbsp;Bemdac&nbsp;brand for the treatment of uncontrolled levels of&nbsp;bad cholesterol.</li>
	<li>In April 2022, AstraZeneca introduced the AZD8233 reduced low-density lipoprotein cholesterol levels by 73% in patients with high-risk hypercholesterolemia in the ETESIAN Phase IIb trial.</li>
</ul>

<h3>Why Purchase the Report?</h3>

<ul>
	<li>To visualize the global dyslipidemia market segmentation based on drug class, distribution channel, and region, as well as understand key commercial assets and players.</li>
	<li>Identify commercial opportunities by analyzing trends and co-development</li>
	<li>Excel data sheet with numerous data points of global dyslipidemia market level with all segments.</li>
	<li>PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.</li>
	<li>Product mapping is available in Excel consisting of key products of all the major players.</li>
</ul>

The global dyslipidemia market report would provide approximately 54 tables, 49 figures, and 182 Pages.

<h3>Target Audience 2024</h3>

<ul>
	<li>Manufacturers/ Buyers</li>
	<li>Industry Investors/Investment Bankers</li>
	<li>Research Professionals</li>
	<li>Emerging Companies</li>
</ul>

<ol>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Definition and Overview</h3>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Executive Summary</h3>

	<ol>
		<li>Snippet by Drug Class</li>
		<li>Snippet by Distribution Channel</li>
		<li>Snippet by Region</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Dynamics</h3>

	<ol>
		<li>Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Increasing Prevalence of Cardiovascular Diseases and Dyslipidemia</li>
				<li>Advanced Therapies for the Treatment&nbsp;</li>
			</ol>
			</li>
			<li>&nbsp;Restraints
			<ol>
				<li>The High Cost for Research &amp; Development</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Industry Analysis&nbsp;</h3>

	<ol>
		<li>Porter&#39;s Five Force Analysis&nbsp;</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Unmet Needs</li>
		<li>PESTEL Analysis</li>
		<li>Patent Analysis</li>
		<li>SWOT Analysis</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Drug Class</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Attractiveness Index, By Drug Class</li>
		</ol>
		</li>
		<li>Statin Drugs*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
			<li>Atorvastatin&nbsp;</li>
			<li>Lovastatin</li>
			<li>Rosuvastatin</li>
			<li>Others</li>
		</ol>
		</li>
		<li>Bile Acid Sequestrants</li>
		<li>Cholesterol Absorption Inhibitors</li>
		<li>Fibrates</li>
		<li>Niacins</li>
		<li>Omega-3 Fatty Acid Derivatives</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Distribution Channel</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Attractiveness Index, By Distribution Channel</li>
		</ol>
		</li>
		<li>Hospital Pharmacies *
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Retail Pharmacies</li>
		<li>Online Pharmacies</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Region</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>UK</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia-Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>South Korea</li>
				<li>Rest of Asia-Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Competitive Landscape</h3>

	<ol>
		<li>Competitive Scenario</li>
		<li>Market Positioning/Share Analysis</li>
		<li>Mergers and Acquisitions Analysis</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Company Profiles</h3>

	<ol>
		<li>&nbsp;AstraZeneca *
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio &amp; Description</li>
			<li>Financial Overview</li>
			<li>Key Developments</li>
		</ol>
		</li>
		<li>Merck &amp; Co., Inc</li>
		<li>Pfizer Inc</li>
		<li>Sanofi</li>
		<li>Abbott</li>
		<li>Mylan N.V.</li>
		<li>Novartis Pharmaceuticals Corporation</li>
		<li>Teva Pharmaceutical Industries Ltd</li>
		<li>Lupin</li>
		<li>Esperion Therapeutics, Inc&nbsp;(LIST NOT EXHAUSTIVE)&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Appendix</h3>

	<ol>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

List of Tables

Table 1 Global Dyslipidemia Market Value, By Drug Class, 2023, 2027 &amp; 2031 (US$ Million)

Table 2 Global Dyslipidemia Market Value, By Distribution Channel, 2023, 2027 &amp; 2031 (US$ Million)

Table 3 Global Dyslipidemia Market Value, By Region, 2023, 2027 &amp; 2031 (US$ Million)

Table 4 Global Dyslipidemia Market Value, By Drug Class, 2023, 2027 &amp; 2031 (US$ Million)

Table 5 Global Dyslipidemia Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 6 Global Dyslipidemia Market Value, By Distribution Channel, 2023, 2027 &amp; 2031 (US$ Million)

Table 7 Global Dyslipidemia Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 8 Global Dyslipidemia Market Value, By Region, 2023, 2027 &amp; 2031 (US$ Million)

Table 9 Global Dyslipidemia Market Value, By Region, 2022-2031 (US$ Million)

Table 10 North America Dyslipidemia Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 11 North America Dyslipidemia Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 12 North America Dyslipidemia Market Value, By Country, 2022-2031 (US$ Million)

Table 13 Asia-Pacific Dyslipidemia Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 14 Asia-Pacific Dyslipidemia Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 15 Asia-Pacific Dyslipidemia Market Value, By Country, 2022-2031 (US$ Million)

Table 16 Europe Dyslipidemia Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 17 Europe Dyslipidemia Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 18 Europe Dyslipidemia Market Value, By Country, 2022-2031 (US$ Million)

Table 19 South America Dyslipidemia Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 20 South America Dyslipidemia Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 21 South America Dyslipidemia Market Value, By Country, 2022-2031 (US$ Million)

Table 22 Middle East and Africa Dyslipidemia Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 23 Middle East and Africa Dyslipidemia Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 24 Middle East and Africa Dyslipidemia Market Value, By Country, 2022-2031 (US$ Million)

Table 25 AstraZeneca: Overview

Table 26 AstraZeneca: Product Portfolio

Table 27 AstraZeneca: Key Developments

Table 28 Merck &amp; Co., Inc: Overview

Table 29 Merck &amp; Co., Inc: Product Portfolio

Table 30 Merck &amp; Co., Inc: Key Developments

Table 31 Pfizer Inc: Overview

Table 32 Pfizer Inc: Product Portfolio

Table 33 Pfizer Inc: Key Developments

Table 34 Sanofi: Overview

Table 35 Sanofi: Product Portfolio

Table 36 Sanofi: Key Developments

Table 37 Abbott: Overview

Table 38 Abbott: Product Portfolio

Table 39 Abbott: Key Developments

Table 40 Mylan N.V.: Overview

Table 41 Mylan N.V.: Product Portfolio

Table 42 Mylan N.V.: Key Developments

Table 43 Novartis Pharmaceuticals Corporation: Overview

Table 44 Novartis Pharmaceuticals Corporation: Product Portfolio

Table 45 Novartis Pharmaceuticals Corporation: Key Developments

Table 46 Teva Pharmaceutical Industries Ltd: Overview

Table 47 Teva Pharmaceutical Industries Ltd: Product Portfolio

Table 48 Teva Pharmaceutical Industries Ltd: Key Developments

Table 49 Lupin: Overview

Table 50 Lupin: Product Portfolio

Table 51 Lupin: Key Developments

Table 52 Esperion Therapeutics, Inc: Overview

Table 53 Esperion Therapeutics, Inc: Product Portfolio

Table 54 Esperion Therapeutics, Inc: Key Developments

List of Figures

Figure 1 Global Dyslipidemia Market Value, 2022-2031 (US$ Million)

Figure 2 Global Dyslipidemia Market Share, By Drug Class, 2023 &amp; 2031 (%)

Figure 3 Global Dyslipidemia Market Share, By Distribution Channel, 2023 &amp; 2031 (%)

Figure 4 Global Dyslipidemia Market Share, By Region, 2023 &amp; 2031 (%)

Figure 5 Global Dyslipidemia Market Y-o-Y Growth, By Drug Class, 2023-2031 (%)

Figure 6 Statin Drugs Dyslipidemia Market Value, 2022-2031 (US$ Million)

Figure 7 Atorvastatin Dyslipidemia Market Value, 2022-2031 (US$ Million)

Figure 8 Lovastatin Dyslipidemia Market Value, 2022-2031 (US$ Million)

Figure 9 Rosuvastatin Dyslipidemia Market Value, 2022-2031 (US$ Million)

Figure 10 Others Dyslipidemia Market Value, 2022-2031 (US$ Million)

Figure 11 Bile Acid Sequestrants Dyslipidemia Market Value, 2022-2031 (US$ Million)

Figure 12 Cholesterol Absorption Inhibitors Dyslipidemia Market Value, 2022-2031 (US$ Million)

Figure 13 Fibrates Dyslipidemia Market Value, 2022-2031 (US$ Million)

Figure 14 Niacins Dyslipidemia Market Value, 2022-2031 (US$ Million)

Figure 15 Omega-3 Fatty Acid Derivatives Dyslipidemia Market Value, 2022-2031 (US$ Million)

Figure 16 Global Dyslipidemia Market Y-o-Y Growth, By Distribution Channel, 2023-2031 (%)

Figure 17 Hospital Pharmacies Distribution Channel in Global Dyslipidemia Market Value, 2022-2031 (US$ Million)

Figure 18 Retail Pharmacies Distribution Channel in Global Dyslipidemia Market Value, 2022-2031 (US$ Million)

Figure 19 Online Pharmacies Distribution Channel in Global Dyslipidemia Market Value, 2022-2031 (US$ Million)

Figure 20 Global Dyslipidemia Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 21 North America Dyslipidemia Market Value, 2022-2031 (US$ Million)

Figure 22 North America Dyslipidemia Market Share, By Drug Class, 2023 &amp; 2031 (%)

Figure 23 North America Dyslipidemia Market Share, By Distribution Channel, 2023 &amp; 2031 (%)

Figure 24 North America Dyslipidemia Market Share, By Country, 2023 &amp; 2031 (%)

Figure 25 Asia-Pacific Dyslipidemia Market Value, 2022-2031 (US$ Million)

Figure 26 Asia-Pacific Dyslipidemia Market Share, By Drug Class, 2023 &amp; 2031 (%)

Figure 27 Asia-Pacific Dyslipidemia Market Share, By Distribution Channel, 2023 &amp; 2031 (%)

Figure 28 Asia-Pacific Dyslipidemia Market Share, By Country, 2023 &amp; 2031 (%)

Figure 29 Europe Dyslipidemia Market Value, 2022-2031 (US$ Million)

Figure 30 Europe Dyslipidemia Market Share, By Drug Class, 2023 &amp; 2031 (%)

Figure 31 Europe Dyslipidemia Market Share, By Distribution Channel, 2023 &amp; 2031 (%)

Figure 32 Europe Dyslipidemia Market Share, By Country, 2023 &amp; 2031 (%)

Figure 33 South America Dyslipidemia Market Value, 2022-2031 (US$ Million)

Figure 34 South America Dyslipidemia Market Share, By Drug Class, 2023 &amp; 2031 (%)

Figure 35 South America Dyslipidemia Market Share, By Distribution Channel, 2023 &amp; 2031 (%)

Figure 36 South America Dyslipidemia Market Share, By Country, 2023 &amp; 2031 (%)

Figure 37 Middle East and Africa Dyslipidemia Market Value, 2022-2031 (US$ Million)

Figure 38 Middle East and Africa Dyslipidemia Market Share, By Drug Class, 2023 &amp; 2031 (%)

Figure 39 Middle East and Africa Dyslipidemia Market Share, By Distribution Channel, 2023 &amp; 2031 (%)

Figure 40 AstraZeneca: Financials

Figure 41 Merck &amp; Co., Inc: Financials

Figure 42 Pfizer Inc: Financials

Figure 43 Sanofi: Financials

Figure 44 Abbott: Financials

Figure 45 Mylan N.V.: Financials

Figure 46 Novartis Pharmaceuticals Corporation: Financials

Figure 47 Teva Pharmaceutical Industries Ltd: Financials

Figure 48 Lupin: Financials

Figure 49 Esperion Therapeutics, Inc: Financials

Dyslipidemia Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Lipid-regulating Drugs Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 June 12

Starting from

Lipodystrophy Market Size, Share, Industry, Trends, and Outlook (2023-2030)

Published: 2023 December 26

Starting from

Antihyperlipidemic Drugs Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 July 09

Starting from